NEW YORK , July 20, 2020 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) announced today an agreement with PTC Therapeutics, Inc. (Nasdaq: PTCT) to acquire a portion of PTC’s royalty interest in risdiplam for a one-time payment of $650 million .

NEW YORK, June 18, 2020 (GLOBE NEWSWIRE) -- Royalty Pharma plc (NASDAQ: RPRX) today announced the closing of the initial public offering of 89,333,920 shares of its Class A ordinary shares pursuant to a registration statement on Form S-1 filed with the U.S.

NEW YORK, June 16, 2020 (GLOBE NEWSWIRE) -- Royalty Pharma today announced the appointment of Dr. Bonnie L. Bassler, PhD to the company's Board of Directors, effective immediately. Dr. Bassler is an accomplished scientist and has served as Chair of the Department of Molecular Biology at Princeton

NEW YORK, June 15, 2020 (GLOBE NEWSWIRE) -- Royalty Pharma plc today announced the pricing of the initial public offering of 77,681,670 shares of its Class A ordinary shares pursuant to a registration statement on Form S-1 filed with the U.S. Securities and Exchange Commission (“SEC”) at a price to

NEW YORK, NY (US) and Cambridge (MA) June 12, 2020  – Royalty Pharma and Agios Pharmaceuticals, Inc. (NASDAQ: AGIO), a leader in the field of cellular metabolism to treat cancer and rare genetic diseases announced that Agios has sold its tiered, sales-based royalty rights on worldwide net sales of

NEW YORK, NY (US) and WUPPERTAL (GERMANY), June 9, 2020  – Royalty Pharma and AiCuris Anti-infective Cures GmbH, a leading company in the discovery and development of drugs against infectious diseases, announced today that they have entered into an agreement whereby Royalty Pharma has acquired a

NEW YORK (NY), May 23, 2020  – Royalty Pharma plc today announced that it has filed a registration statement on Form S-1 with the U.S. Securities and Exchange Commission (the “SEC”) relating to its proposed initial public offering of its Class A ordinary shares.

NEW YORK (NY) and BOSTON (MA), March 5, 2020  – Royalty Pharma announced today that it has acquired Massachusetts General Hospital’s (MGH) royalty interest in Entyvio (vedolizumab) for $94 million. Entyvio is a monoclonal antibody that is used in the treatment of ulcerative colitis and Crohn’s

NEW YORK (NY), February 28, 2020  – Royalty Pharma announced today that Chris Hite has agreed to join the Company as Executive Vice President and Vice Chairman. Chris joined Citi as Global Head of Healthcare Investment Banking in 2008 and most recently served as Vice Chairman and Global Head of

NEW YORK – January 28, 2020 –  Royalty Pharma, the largest acquiror of biopharmaceutical royalties and a leading funder of innovation across the biopharmaceutical industry, announced today that George Grofik has been appointed Senior Vice President, Head of Investor Relations and Communications.